Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Penn Medicine (University of Pennsylvania)

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1358
Shown on this page
12
Current sort
Recently updated
Campus scope
Penn Medicine (University of Pennsylvania), Philadelphia, PA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Penn Medicine (University of Pennsylvania), Philadelphia, PA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 709–720 of 1,358 matching trials with a site at Penn Medicine (University of Pennsylvania), Philadelphia, PA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Not applicable Interventional

A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

NCT04831580
Status at this site: Recruiting
Conditions
Cervical Cancer
Interventions
da Vinci, open surgery
Device · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
133
States / cities
Goodyear, Arizona • Duarte, California • Encinitas, California + 87 more
Active, not recruiting Not applicable Interventional

Responsive Neurostimulation For Loss Of Control Eating

NCT03868670
Site status not listed — check the official record
Conditions
Loss of Control Eating, Obesity, Morbid
Interventions
responsive neurostimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Stanford, California • Philadelphia, Pennsylvania
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Early-onset Alzheimer's Disease Study Protocol

NCT03507257
Site status not listed — check the official record
Conditions
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Flortaucipir, Florbetaben, Fluorodeoxyglucose
Drug
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 64 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
18
States / cities
Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Active, not recruiting Phase 3 Interventional Results available

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

NCT00644228
Site status not listed — check the official record
Conditions
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
496
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 337 more
Recruiting No phase listed Observational

A Clinical Study of the TSX Dental Implant System (Xpresso)

NCT06571812
Status at this site: Active, not recruiting
Conditions
Tooth Loss
Interventions
TSX
Device
Lead sponsor
ZimVie
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Timeline
2024 – 2028
U.S. locations
2
States / cities
Columbus, Ohio • Philadelphia, Pennsylvania
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, Glioma, Oligoastrocytoma, Oligodendroglioma, WHO Grade 3 Glioma
Interventions
Biospecimen Collection, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Procedure · Radiation · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
34
States / cities
Birmingham, Alabama • Boca Raton, Florida • Miami, Florida + 27 more
Conditions
Solid Tumor
Interventions
ROSE12, Atezolizumab, Pembrolizumab
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Philadelphia, Pennsylvania • Providence, Rhode Island • Nashville, Tennessee + 2 more
Recruiting Not applicable Interventional

Adapting the Penny Chatbot for Perinatal OUD Patients: COPILOT

NCT06969261
Status at this site: Recruiting; Not yet recruiting
Conditions
Perinatal Opioid Use Disorder, Opioid Use Disorder
Interventions
Penny COPILOT
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Recruiting Phase 3 Interventional

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

NCT07038200
Status at this site: Active, not recruiting
Conditions
Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Dystrophy, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome
Interventions
AOC-1020, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Orange, California • Palo Alto, California • Denver, Colorado + 11 more
Conditions
Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic, Aneurysmal Disease, Aorta, Thoracic Pathologies
Interventions
Rapidlink
Device
Lead sponsor
Vascutek Ltd.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Recruiting No phase listed Observational Accepts healthy volunteers

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

NCT04477785
Status at this site: Recruiting
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
30 Years and older
Enrollment
4,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2033
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Active, not recruiting Phase 2 Interventional

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

NCT03456843
Site status not listed — check the official record
Conditions
Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Antiandrogen Therapy, Docetaxel, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 4 more

About this Penn Medicine (University of Pennsylvania) institution page

What this page lists
ClinicalTrials.gov records that list Penn Medicine (University of Pennsylvania) in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by University of Pennsylvania at any site, browse by condition, or browse by U.S. city.